Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Receives FDA approval for private label pseudoephedrine extended-release tablets, 120 mg (ANDA 75-153) on Feb. 26. The product is Perrigo's first ANDA approval for an extended-release delivery system. The reference drug is Warner-Lambert's Sudafed 12 Hour Extended-release caplets. FDA indicated ANDA suitability in an Oct. 29, 1997 Federal Register notice ("The Tan Sheet" Nov. 3, 1997, p. 18). Eurand America filed a citizen petition in June 1997 requesting clearance to file an application for the product
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel